A 68-kilodalton (kd) outer membrane protein antigen of Bordetella bronchiseptica has been identified by using monoclonal antibodies that recognized two nonoverlapping determinants. Antibody BBO5 also reacted with homologous proteins from Bordetella pertussis and Bordetella parapertussis but not with another 12 organisms from various bacterial genera. Passive injection of BB05 antibody protected mice from aerosol infection with B. bronchiseptica as shown by reduced mortality and reduced pathology of turbinate bones. The 68-kd B. bronchiseptica antigen was purified by BB05-based affinity chromatography and evaluated for its potency to immunize mice actively against either intraperitoneal or aerosol challenge with B. bronchiseptica. Immunization with the 68-kd antigen in incomplete Freund adjuvant significantly reduced the levels of mortality in intraperitoneally challenged mice. In the aerosol infection model, injection of the 68-kd antigen with complete or incomplete Freund adjuvant or saponin reduced the bacterial counts in the lungs of infected mice. These results suggest that the 68-kd protein may represent a potential "protective" antigen of B. bronchiseptica.
Bordetella bronchiseptica is a microorganism associated with respiratory infections in animals, particularly atrophic rhinitis (AR) of pigs (8, 23) . This disease is characterized by atrophy of the nasal turbinate bones, pneumonia, and growth retardation (1, 12) . Vaccination of sows and piglets with Bordetella bronchiseptica vaccines has produced some positive results, although no detailed information is available as to which bacterial components are responsible for inducing protective immunity (reviewed in reference 7). A correlation has been found previously between antibody titers to proteins present in a cell-surface antigen (CSA) preparation from Bordetella bronchiseptica and resistance to AR in piglets born from immunized sows (P. Novotny, A. P. Chubb, K. Cownley, and J. A. Montaraz, manuscript in preparation). This extract contains lipopolysaccharide, outer membrane proteins, and fibrilar material. For further investigation of the molecular nature of protective antigens contained among the components of CSA, monoclonal antibodies (MABs) were raised against components of the extract and tested for passive protection of mice against Bordetella bronchiseptica infection. The corresponding antigen was purified by MAB-based affinity chromatography and appraised for protective potency by active immunization. Two murine models of infection were adopted: (i) intraperitoneal (i.p.) injection of the microorganism as used previously to test whole-cell Bordetella bronchiseptica vaccines (9, 22) , and (ii) a newly developed aerosol infection model resulting in pneumonia, AR, and death (Novotny et al., in preparation). Significant protection was conferred by one protein described in detail elsewhere (P. Novotny, A. P. Chubb, K. Cownley, and J. A. Montaraz, submitted for publication). Briefly, the extracts were prepared by the following methods.
CSAs. CSA was prepared by a modified technique used for the preparation of K-antigen from E. coli (17) . Essentially, Bordetella bronchiseptica cells at the exponential growth phase were incubated for 30 min at 60°C and sedimented by centrifugation for 30 min at 10 ,000 x g. The supernatant was centrifuged for 2 h at 50,000 x g, cooled, and precipitated by 67% (vol/vol) ethanol. The precipitate was dissolved in distilled water and cleared of insoluble residues by centrifugation for 2 h at 100,000 x g. The supernatant fraction (CSA) was stored freeze-dried.
Acid glycine hydrolysate. Cells were suspended in 250 mM glycine-5 mM EDTA buffer (pH 3), incubated for 18 h at 37°C, neutralized, and centrifuged. One volume of supernatant, mixed with 2 volumes of acetone, was incubated for 3 h at -20°C, and the resulting precipitate was centrifuged at 4,000 x g and dissolved in water. The solution, freed of insoluble material by centrifugation, was stored freezedried.
Outer membrane vesicles (OMVs). OMVs were prepared by differential centrifugation methods described previously for the fractionation of Bordetella pertussis (16) . Cells were broken with a rotary disintegrator (15) , and the OMV fraction was sedimented by centrifugation at 50,000 x g for 1 h. This material, when centrifuged through a 55% Percoll solution, showed a peak in the 1.032 density region (Novotny et al., submitted for publication).
Production of MABs. BALB/c mice were immunized i.p. with 0.5-ml doses of a Bordetella bronchiseptica vaccine diluted 1:10 in phosphate-buffered saline at 26-day intervals. Mice were challenged with the same antigen 2 to 3 days before fusion.
Fusions were performed by using spleen cells from immunized mice and P3-NSI/1-Ag4-1 myeloma cells in the presence of polyethylene glycol (6) . Cells were plated in RPMI medium (GIBCO Laboratories) supplemented with 10% fetal calf serum, 0.1 mM hypoxanthine, 15 mM thymidine, and 0.43 M aminopterin (HAT medium). Tissue culture supernatants were screened for antibody activity by a solid-phase radioimmunoassay (RIA), using CSA as antigen. Positive cultures were cloned by limiting dilution and expanded either in culture to produce maximum growth medium or as ascitic tumours in the peritoneal cavities of mice. The globulin fraction was prepared from ascitic fluid by precipitation in the presence of 18% (wt/vol) sodium sulfate and adjusted to a 5-mg/ml concentration on the basis of protein content (10 Murine models of Bordetella bronchiseptica infection. MF-1 specific-pathogen-free (OLAC), 3-week-old mice were used throughout the study.
(i) Intraperitoneal infection. The virulent strain of Bordetella bronchiseptica 134, originally isolated from a pig suffering from AR, was used for the challenge of mice. Bacteria were grown on Cohen-Wheeler agar containing 5% horse blood and were harvested after 18 h of incubation at 37°C. The cells were suspended in PBS, and the suspension was adjusted to an optical density of 0.5 at 650 nm, equivalent to a bacterial concentration of 2 x 109 CFU/ml. Mice were injected with 0.5 ml of this suspension with 90 min of its reading, and mortality was recorded daily for a period of 10 days.
(ii) Aerosol infection. The aerosol infection model has been described comprehensively elsewhere (Novotny et al., submitted for publication). Briefly, mice were exposed to an aerosol generated from a Bordetella bronchiseptica suspension containing 2 x 109 CFU/ml. After 10 min of exposure, a very consistent count of 103 to 104 CFU of B. bronchiseptica per lung was obtained 30 to 60 min after infection. Mortality was recorded daily for 21 days, and periodically mice were killed for the assay of CFU in the lungs. For this purpose, the right lung was aseptically removed and homogenized. Dilutions of the homogenate were dropped onto Cohen-Wheeler agar and counted after 48 h of incubation at 370C.
Determination of AR was carried out 5 weeks postinfection. Mice killed by cervical dislocation were decapitated, the hard palate was exposed, and the skull was frozen. The skull was cut twice in front of and behind the most prominent ridge of the rugae palatinae with a tungsten carbide circular saw driven by a dental drill. Three adjacent sections were obtained: the nose end (snout), a 1-mm-thick intermediary slice, and the skull end. The first two sections only were examined under a dissecting microscope immediately after cutting (i.e., while still frozen) and after fixation in 10% Formalin. In normal mice, the turbinate bones give a solid appearance, with very narrow gaps between the turbinates and the nasal septum. As a result of AR, the gaps are enlarged and cavities, very often asymmetrical, have developed.
Determination of serum antibody levels. Sera were titrated in a solid-phase RIA. Polyvinyl microtiter plates (Dynatech Laboratories), coated with either CSA (1 ,ug in 100 pAl of PBS per well) or 68-kd antigen (0.5 ,ug in 50 ,u of PBS per well), were reacted with dilutions of mice sera for 2 to 4 h at 40C, A competition RIA was set up to investigate whether BB05 and BB07 reacted with the same or distinct epitopes of the 68-kd molecule. In principle, if the two antibodies reacted with the same epitope, binding of the unlabeled antibody would prevent the binding of the second radiolabeled antibody. However, if the two antibodies reacted with different, nonoverlapping epitopes, the binding of the radiolabeled antibody would be detected regardless of the presence of the unlabeled antibody. The results of reciprocal competition assays of radiolabeled BB05 or BB07 showed that the homologous antibody competed with the binding of the corresponding iodinated globulin fraction in a dose-response fashion (Fig. 2) . However, cross-competition was not observed, indicating that each MAB reacted with a different nonoverlapping epitope on the 68-kd molecule.
Location of the 68-kd antigen within bacteria. The CSA preparation of Bordetella bronchiseptica contains lipopolysaccharides, fibers, and outer membrane proteins, of which the latter component seemed the most likely to contain the 68-kd molecule. To test this assumption, OMVs were run in SDS-PAGE and the electroblot was reacted with MAB BB05. Binding to the 68-kd component of the OMV preparation was observed (Fig. 1, lane 4) , suggesting that this antigen is a component of the outer membrane of Bordetella bronchiseptica. An analysis of the enzymatic susceptibility of the 68-kd antigen showed that the BB05 epitope was destroyed by Bacillus subtilis protease or trypsin treatment. However, the epitope was resistant to neuraminidase or sodium periodate oxidation (data not shown). These results further support the view that the 68-kd antigen is probably of a protein nature.
Purification of the 68-kd antigen of Bordetella bronchiseptica by MAB BB05-based affinity chromatography. The 68-kd antigen was purified from an acid glycine hydrolysate extract of Bordetella bronchiseptica. Preliminary experiments suggested that passage of the extract through an anionic exchange column eliminates certain bacterial components that may stick to Sepharose affinity chromatography columns. Therefore, the Bordetella bronchiseptica extract was first passed through a DEAE-Trisacryl column (LKB Instruments Inc.), and the filtrate was subsequently applied to the BB05-based affinity chromatography column. By the use of 327 ml of starting material (0.64 mg of protein per ml) for consecutive affinity purification, three fractions eluted with 3 M NaSCN were obtained and evaluated by SDS-PAGE and immunoblot. A considerable degree of purity was achieved, particularly in the eluates of the first and second chromatographic runs (Fig. 3A) . The corresponding immunoblot of fractions is also shown (Fig. 3B) (Fig. 4) . The initial 2.3 x 104 CFU count immediately after challenge in the control group rose to 4.5 x 109 at day 7 postinfection. Though no difference was apparent at day 2 or 5, the CFU counts in the lungs of immunized mice were lower by at least two orders of magnitude when compared with controls at the peak (day 7) of infection. The mortality of control mice ensued after the peak of CFU values was reached, i.e., during week 2 after infection. However, by day 13 postinfection, the bacterial load was similar in all groups. Although the bacterial counts in immunized and control mice were similar at day 27, the survival in the passively immunized groups (80 to 90%) was significantly better than in controls (45%). Five weeks after challenge, all surviving mice were sacrificed and their turbinate bones were examined for the presence of AR. All control mice showed signs of AR, but only one of eight mice (P = 0.015) injected with undiluted BB05 showed signs of the disease ( Table 2 , experiment 1).
In subsequent experiments, the contact infectivity of passively immunized and control aerosol-infected mice was investigated. Clean, nonimmunized mice were mixed with the experimental and control groups and monitored for mortality and incidence of AR ( None/i.p. (14) Challenge control Given 28 days after the first immunization. (3) showed that the three species possessed common 0 antigens but that each of them had its own specific 0 antigen in addition to the overlapping K antigens. More recently, Ezzell et al. (4) have studied the envelope proteins of bordetellas. They found that all three species possessed a major protein of molecular weight in the range of 37,000 to 41,000 and at least six other proteins of lower molecular weight. These proteins could not be assigned to either inner or outer membranes. Robinson and Hawkins (19) found that the major envelope proteins of Bordetella bronchiseptica and Bordetella parepertussis had Passive immunization with MABs BB05 and BB07 was tested in Bordetella bronchiseptica aerosol-infected mice. Antibody BB05 showed a protective effect in terms of reduced mortality, incidence of AR, and number of lung CFU counts. The latter is of particular interest since the effect of the passively infected antibody was not patent until day 5 postinfection. Three possibilities may be put forward to explain this time course.
(i) During the first days of infection, the MAB could not reach the tissue in which the microorganisms were multiplying. However, once an inflammatory response developed, changes in permeability allowed the plasma exudation and the penetration of antibody into the tissues.
(ii) The lag period may represent the time needed for the recruitment of leukocytes and macrophages for the antibody-mediated opsonization.
(iii) Although Bordetella bronchiseptica is considered an extracellular pathogen with marked predilection for the ciliated epithelium of the respiratory tract (2, 25) , it is possible that intracellular infection may also take place and hence that antibodies could not reach the bacteria in tissues until sufficient damage exposing the microorganism had occurred.
Irrespective of the lag effect of the MAB, it is pertinent that Bordetella bronchiseptica persist in the lungs of infected mice for at least 35 days postinfection. It has been reported that immunization of mice with whole Bordetella bronchiseptica cells followed by intranasal infection effectively clears the organisms from the lungs and protects against mortality, whereas organisms still persist in the nasal davity for up to 60 to 150 days after challenge (21) . Although passive injection of MAB BB05 did not eradicate the infection, it prevented mortality, the development of AR, and the spread from infected to noninfected mice. It is conceivable that the passive protection obtained in this study with MAB BB05 may be mediated by mechanisms similar to those that are effective in piglets receiving immune colostrum from sows (11, 13) . Presumably, colostral antibodies (79% immunoglobulin G and 14% immunoglobulin A from total immunoglobulin (18) are traversing the intestinal mucosa and the general circulation from which they have to reach the respiratory tract to exercise protective immunity.
Antibody BB07, in contrast to MAB BB05, failed to protect mice against aerosol infection. This result was particularly interesting considering that both antibodies react with the same antigen. Although the explanation is not known, it is possible to speculate that the two epitopes may differ in their orientation on the bacterial cell surface.
Immunization with the purified 68-kd antigen against i.p. infection resulted in 37% protection when the antigen was injected in IFA. Immunization resulted in a significant reduction in the number of CFU of Bordetella bronchiseptica in the lungs of aerosol-infected mice. However, the evaluation of results in preventing AR was hampered by the apparent resistance of 4-week-old mice to develop the disease. Others have observed that 5-day-old intranasally inoculated mice developed AR, whereas 7-to 14-day-old mice were resistant (20) . A 
